{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:01:00Z","timestamp":1792659660602,"version":"4.5.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2003,6,24]],"date-time":"2003-06-24T00:00:00Z","timestamp":1056412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,6,24]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>Advances in understanding pathogenesis and developing new therapies are hastened by the use of effective animal models of disease. In inflammatory bowel disease, such as Crohn's disease, a variety of models have been used, including the IL-10 knockout mouse. However, in order to be truly valuable, the models need to respond to existing therapy in a way which resembles the human disease. In the light of recent developments, in which refractory Crohn's disease responds well to anti-TNF antibody therapy, we set out to validate the IL-10 knockout model of Crohn's disease by examining its response to anti-TNF therapy. We developed a new scoring system for IL-10 knockout mice, similar to the Crohn's Disease Activity Index in humans, analysed stool samples for cytokines and compared the findings with histology. We found that anti-TNF antibody therapy starting at 4\u2003weeks markedly ameliorated the disease, as judged by the clinical score or by histological analysis of the gut. Furthermore, analysis of stool samples for cytokines revealed a marked diminution of inflammatory cytokines, adding a further accurate measure of the improvement. This model may thus be useful for evaluating other therapeutic modalities of relevance to Crohn's disease.<\/jats:p>","DOI":"10.1046\/j.1365-2249.2003.02193.x","type":"journal-article","created":{"date-parts":[[2004,12,21]],"date-time":"2004-12-21T21:53:19Z","timestamp":1103665999000},"page":"38-43","source":"Crossref","is-referenced-by-count":90,"title":["Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis"],"prefix":"10.1093","volume":"133","author":[{"given":"T","family":"SCHEININ","sequence":"first","affiliation":[{"name":"Fourth Department of Surgery, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D M","family":"BUTLER","sequence":"additional","affiliation":[{"name":"Kennedy Institute of Rheumatology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"SALWAY","sequence":"additional","affiliation":[{"name":"Kennedy Institute of Rheumatology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"SCALLON","sequence":"additional","affiliation":[{"name":"Centocor Inc., Malvern, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"FELDMANN","sequence":"additional","affiliation":[{"name":"Kennedy Institute of Rheumatology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2003,6,24]]},"reference":[{"key":"2022011222240481700_b1","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/jama.1932.02740680019005","article-title":"Regional ileitis, a pathological and clinical entity","volume":"99","author":"Crohn","year":"1932","journal-title":"J Am Med Assoc"},{"key":"2022011222240481700_b2","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1111\/j.1572-0241.1999.01371.x","article-title":"Epidemiology of Crohn's disease in Israel: a survey of Israeli kibbutz settlements","volume":"94","author":"Niv","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"2022011222240481700_b3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/gut.39.1.69","article-title":"Association of HLA class II genes with susceptibility to Crohn's disease","volume":"39","author":"Danze","year":"1996","journal-title":"Gut"},{"key":"2022011222240481700_b4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/gut.43.2.210","article-title":"Analysis of MHC class II DP, DQ and DR alleles in Crohn's disease","volume":"43","author":"Cariappa","year":"1998","journal-title":"Gut"},{"key":"2022011222240481700_b5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/gut.44.4.519","article-title":"Linkage of Crohn's disease to the major histocompatibility complex region is detected by multiple non-parametric analyses","volume":"44","author":"Yang","year":"1999","journal-title":"Gut"},{"key":"2022011222240481700_b6","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0198-8859(99)00134-2","article-title":"HLA class II haplotype associations with inflammatory bowel disease in Jewish (Ashkenazi) and non-Jewish caucasian populations","volume":"61","author":"Trachtenberg","year":"2000","journal-title":"Hum Immunol"},{"key":"2022011222240481700_b7","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/gut.31.7.795","article-title":"Plasma interleukin-2 and a soluble\/shed interleukin-2 receptor in serum of patients with Crohn's disease","volume":"31","author":"Brynskov","year":"1990","journal-title":"Gut"},{"key":"2022011222240481700_b8","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s002689900401","article-title":"Cytokines in inflammatory bowel disease","volume":"22","author":"Rogler","year":"1998","journal-title":"World J Surg"},{"key":"2022011222240481700_b9","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1034\/j.1399-0039.1999.540408.x","article-title":"Interleukin-10 (IL-10) genotypes in inflammatory bowel disease","volume":"54","author":"Tagore","year":"1999","journal-title":"Tissue Antigens"},{"key":"2022011222240481700_b10","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0960-9822(00)00060-9","article-title":"Inflammatory bowel disease in knockout mice","volume":"4","author":"MacDonald","year":"1994","journal-title":"Current Biol"},{"key":"2022011222240481700_b11","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0952-7915(99)00032-1","article-title":"Animal models of mucosal inflammation ant their relation to human inflammatory bowel disease","volume":"11","author":"Blumberg","year":"1999","journal-title":"Curr Op Immunol"},{"key":"2022011222240481700_b12","first-page":"1503","article-title":"Inflammatory bowel disease in C.B-17 scid mice reconstituted with the CD45RBhigh subset of CD4+ T cells","volume":"148","author":"Leach","year":"1996","journal-title":"Am J Pathol"},{"key":"2022011222240481700_b13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/jlb.61.4.389","article-title":"Studies with IL-10 -\/- mice: an overview","volume":"61","author":"Rennick","year":"1997","journal-title":"J Leukoc Biol"},{"key":"2022011222240481700_b14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0140-6736(92)90999-J","article-title":"Tumor necrosis factor alpha in stool as a marker of intestinal inflammation","volume":"339","author":"Braegger","year":"1992","journal-title":"Lancet"},{"key":"2022011222240481700_b15","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.4049\/jimmunol.152.12.5883","article-title":"Inflammatory granuloma formation is mediated by TNF-alpha inducible intercellular adhesion molecule-1","volume":"152","author":"Lukacs","year":"1994","journal-title":"J Immunol"},{"key":"2022011222240481700_b16","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.1780361206","article-title":"Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF\u03b1","volume":"36","author":"Elliott","year":"1993","journal-title":"Arthritis Rheum"},{"key":"2022011222240481700_b17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0016-5085(95)90277-5","article-title":"Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)","volume":"109","author":"Van Dullemen","year":"1995","journal-title":"Gastroenterology"},{"key":"2022011222240481700_b18","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"2022011222240481700_b19","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"key":"2022011222240481700_b20","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1053\/gast.1997.v113.pm9247454","article-title":"Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group","volume":"113","author":"Van Deventer","year":"1997","journal-title":"Gastroenterology"},{"key":"2022011222240481700_b21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0016-5085(99)70550-0","article-title":"Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease","volume":"117","author":"Sands","year":"1999","journal-title":"Gastroenterology"},{"key":"2022011222240481700_b22","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/1074-7613(94)90045-0","article-title":"Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhigh CD4+ T cells","volume":"1","author":"Powrie","year":"1994","journal-title":"Immunity"},{"key":"2022011222240481700_b23","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0090-1229(95)90144-2","article-title":"Interleukin-10 gene knock-out mice. a model of chronic inflammation","volume":"76","author":"Rennick","year":"1995","journal-title":"Clin Immunol Immunopathol"},{"key":"2022011222240481700_b24","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1080\/00365529850171891","article-title":"Detection of pro- and anti-inflammatory cytokines in stools of patients with IBD","volume":"33","author":"Saiki","year":"1998","journal-title":"Scand J Gastroenterol"},{"key":"2022011222240481700_b25","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/(SICI)1521-4141(199907)29:07<2205::AID-IMMU2205>3.0.CO;2-Z","article-title":"Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis","volume":"29","author":"Butler","year":"1999","journal-title":"Eur J Immunol"},{"key":"2022011222240481700_b26","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/0016-5085(79)90383-4","article-title":"National cooperative Crohn's disease study. study design and conduct of the study","volume":"77","author":"Winship","year":"1979","journal-title":"Gastroenterology"},{"key":"2022011222240481700_b27","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1128\/iai.63.8.3079-3087.1995","article-title":"Down-regulation of gamma interferon, tumor necrosis factor type I, interleukin 1 (IL-1) type I, IL-3, IL-4, and transforming growth factor \u03b2 type I receptors at the local site during the acute phase of shigella infection","volume":"63","author":"Raqib","year":"1995","journal-title":"Infect Immun"},{"key":"2022011222240481700_b28","doi-asserted-by":"crossref","first-page":"9784","DOI":"10.1073\/pnas.89.20.9784","article-title":"Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis","volume":"89","author":"Williams","year":"1992","journal-title":"Proc Natl Acad U S A"},{"key":"2022011222240481700_b29","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1172\/JCI118861","article-title":"Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4+ TH1-like responses","volume":"98","author":"Berg","year":"1996","journal-title":"J Clin Invest"},{"key":"2022011222240481700_b30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0065-2776(08)60891-3","article-title":"Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis","volume":"64","author":"Feldmann","year":"1997","journal-title":"Adv Immunol"},{"key":"2022011222240481700_b31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1365-3083.2000.00657.x","article-title":"Immunotherapy of Crohn's disease","volume":"51","author":"Van Deventer","year":"2000","journal-title":"Scand J Immunol"},{"key":"2022011222240481700_b32","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","article-title":"Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease","volume":"117","author":"Rutgeerts","year":"1999","journal-title":"Gastroenterology"},{"key":"2022011222240481700_b33","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1073\/pnas.91.7.2762","article-title":"Synergy between anti-CD4 and antiTNF in the amelioration of established collagen-induced arthritis","volume":"91","author":"Williams","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022011222240481700_b34","first-page":"S295","article-title":"A double blind, placebo-controlled, ascending dose trial of the recombinant humanised anti-TNF\u03b1 antibody CDP571 in patients with rheumatoid arthritis (RA): a preliminary report","volume":"37","author":"Rankin","year":"1994","journal-title":"Arth Rheum"},{"key":"2022011222240481700_b35","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1073\/pnas.65.3.551","article-title":"Cellular sites of immunologic unresponsiveness","volume":"65","author":"Chiller","year":"1970","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2249.2003.02193.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2249.2003.02193.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/133\/1\/38\/42143093\/j.1365-2249.2003.02193.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/133\/1\/38\/42143093\/j.1365-2249.2003.02193.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:56:55Z","timestamp":1682902615000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/133\/1\/38\/6469368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,6,24]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2003,6,24]]},"published-print":{"date-parts":[[2003,6,24]]}},"URL":"https:\/\/doi.org\/10.1046\/j.1365-2249.2003.02193.x","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2003,7]]},"published":{"date-parts":[[2003,6,24]]}}}